Zeke Capital Advisors’s Biogen BIIB Stock Holding History

Zeke Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,141	Closed	-$240K	–	487
2022 Q1	$240K	Buy	+1,141	New	+$248K	0.01%	434
2020 Q1	–	Sell	-1,048	Closed	-$311K	–	266
2019 Q4	$311K	Sell	1,048 -13	-1%	-$3.61K	0.03%	459
2019 Q3	$247K	Sell	1,061 -3,446	-76%	-$802K	0.02%	483
2019 Q2	$1.05M	Buy	4,507 +23	+0.5%	+$5.31K	0.1%	169
2019 Q1	$1.06M	Sell	4,484 -210	-4%	-$66.1K	0.1%	169
2018 Q4	$1.41M	Sell	4,694 -3,562	-43%	-$1.14M	0.14%	138
2018 Q3	$2.92M	Hold	8,256	–	–	0.24%	71
2018 Q2	$2.4M	Buy	8,256 +4,461	+118%	+$1.25M	0.22%	78
2018 Q1	$1.04M	Sell	3,795 -1,659	-30%	-$515K	0.1%	190
2017 Q4	$1.74M	Buy	5,454 +1,689	+45%	+$542K	0.18%	94
2017 Q3	$1.18M	Buy	3,765 +2,340	+164%	+$693K	0.16%	102
2017 Q2	$387K	Sell	1,425 -59	-4%	-$15.6K	0.07%	162
2017 Q1	$406K	Buy	1,484 +448	+43%	+$127K	0.08%	144
2016 Q4	$294K	Buy	+1,036	New	+$307K	0.08%	138

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Zeke Capital Advisors's BIIB Position: Q2 2022 in Review

Zeke Capital Advisors sold out of Biogen (BIIB) in Q2 2022, closing a stake of 1,141 shares — an estimated $240K sold.

Zeke Capital Advisors first reported a position in BIIB in Q4 2016 and held it in 14 quarters. The position peaked at $2.92M in Q3 2018. 927 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

Zeke Capital Advisors reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
Zeke Capital Advisors sold 1,141 Biogen shares in Q2 2022, an estimated $240K.
Zeke Capital Advisors first reported a position in Biogen in Q4 2016 and held it in 14 quarters.
Zeke Capital Advisors's Biogen position peaked at $2.92M in Q3 2018.
927 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Zeke Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.